Beneficence
Protecting people with lung disease from the moral distress of having to use inhalers that fund the tobacco industry, an industry which is a key cause of the development and progression of lung disease, is an important benefit of switching. So too is reinforcing the policy that the tobacco industry needs to be excluded from healthcare, based on its long and extensively documented history of dishonesty and diversion around the harms of smoking. It challenges the attempt by the industry to divert attention from the actions that are actually needed to end smoking, achieving the UK’s Smokefree 2030 ambition, such as a polluter-pays levy on tobacco industry profits and raising the legal age of sale to 2113.